MedPage Today on MSN
CAR-like T cells enhance tumor response in gastroesophageal cancer
Early evidence suggests safety, efficacy, while awaiting data on durability in broader pop ...
AstraZeneca had already bagged the rights to the AbelZeta Pharma-partnered CAR-T cell therapy for most of the world. | The ...
Hosted on MSN
Enhanced CAR T cells emerge from genetic screening
CAR T cells are patient-derived, genetically engineered immune cells. They are "living drugs" and constitute a milestone in modern medicine. Equipping T cells, a key cell type of the immune system, ...
Magnetic nanoparticles engineered T cells inside living mice and guided them into solid tumors, achieving over 90% tumor ...
The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...
A personal reflection on the promise and limits of CAR T therapy—its breakthroughs, failures, scientific bottlenecks, and what must change to truly save more lives.
Researchers at the University of Chicago have developed a "universal" chimeric antigen receptor (CAR) platform that offers enhanced safety, adaptability, and the potential to overcome long-standing ...
A pioneering preclinical study has shown that CAR T cell therapy-a personalized form of immunotherapy used in cancer treatment-could be a highly effective tool against atherosclerosis, the condition ...
In vivo CAR T-cell therapies could improve access by eliminating complex logistics and reducing costs, making them more accessible to underserved populations. Traditional CAR T-cell therapies face ...
Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer in mice—effectively ...
Members of the CAR T Vision Steering Committee outline key issues around US and EU reimbursement and discuss potential solutions Since their launch in 2017, chimeric antigen receptor T-cell therapies ...
In a clinical trial of 7 patients, anti-BCMA only CAR-T cell treated patients with refractory lupus nephritis safely and effectively. Anti-B cell maturation antigen (BCMA)-targeting chimeric antigen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results